HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Neutral 53.2%

Neg 0% Neu 53.2% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target from $30 to $17.